Neuroendocrine Prostate Cancer

Daniel C. Parker; Alexander Kutikov

doi:10.1016/B978-0-12-800077-9.00018-9

Neuroendocrine Prostate Cancer

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Neuroendocrine differentiation (NED) in prostate cancer refers to prostate tissue in men with aggressive, hormone refractory disease that contains an abundance of neuroendocrine cells. Such cells are part of an otherwise dispersed regulatory network that is normally present in the pulmonary, gastrointestinal, and immune systems. These cells are unique for their intracytoplasmic granules containing a variety of peptide hormones. NED is associated with extremely poor prognosis and is remarkable for androgen-independent growth of tumor cells.

Original language	English
Title of host publication	Prostate Cancer: Science And Clinical Practice, 2nd Edition
Subtitle of host publication	Science and Clinical Practice: Second Edition
Editors	JH Mydlo, CJ Godec
Publisher	Elsevier Inc.
Pages	149-155
Number of pages	7
ISBN (Print)	9780128000779
DOIs	https://doi.org/10.1016/B978-0-12-800077-9.00018-9 https://doi.org/10.1016/B978-0-12-800077-9.00018-9
State	Published - 2016

Keywords

Androgen independent
Chromogranin
Hormone refractory
Neuroendocrine
Prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Cite this

@inbook{66da589649b844e38e2092a0907fe061,

title = "Neuroendocrine Prostate Cancer",

abstract = "Neuroendocrine differentiation (NED) in prostate cancer refers to prostate tissue in men with aggressive, hormone refractory disease that contains an abundance of neuroendocrine cells. Such cells are part of an otherwise dispersed regulatory network that is normally present in the pulmonary, gastrointestinal, and immune systems. These cells are unique for their intracytoplasmic granules containing a variety of peptide hormones. NED is associated with extremely poor prognosis and is remarkable for androgen-independent growth of tumor cells.",

keywords = "Androgen independent, Chromogranin, Hormone refractory, Neuroendocrine, Prostate cancer",

author = "Parker, {Daniel C.} and Alexander Kutikov",

year = "2016",

doi = "10.1016/B978-0-12-800077-9.00018-9",

language = "English",

isbn = "9780128000779",

pages = "149--155",

editor = "JH Mydlo and CJ Godec",

booktitle = "Prostate Cancer: Science And Clinical Practice, 2nd Edition",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Neuroendocrine Prostate Cancer

AU - Parker, Daniel C.

AU - Kutikov, Alexander

PY - 2016

Y1 - 2016

N2 - Neuroendocrine differentiation (NED) in prostate cancer refers to prostate tissue in men with aggressive, hormone refractory disease that contains an abundance of neuroendocrine cells. Such cells are part of an otherwise dispersed regulatory network that is normally present in the pulmonary, gastrointestinal, and immune systems. These cells are unique for their intracytoplasmic granules containing a variety of peptide hormones. NED is associated with extremely poor prognosis and is remarkable for androgen-independent growth of tumor cells.

AB - Neuroendocrine differentiation (NED) in prostate cancer refers to prostate tissue in men with aggressive, hormone refractory disease that contains an abundance of neuroendocrine cells. Such cells are part of an otherwise dispersed regulatory network that is normally present in the pulmonary, gastrointestinal, and immune systems. These cells are unique for their intracytoplasmic granules containing a variety of peptide hormones. NED is associated with extremely poor prognosis and is remarkable for androgen-independent growth of tumor cells.

KW - Androgen independent

KW - Chromogranin

KW - Hormone refractory

KW - Neuroendocrine

KW - Prostate cancer

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000413427900019&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/B978-0-12-800077-9.00018-9

DO - 10.1016/B978-0-12-800077-9.00018-9

M3 - Chapter

SN - 9780128000779

SP - 149

EP - 155

BT - Prostate Cancer: Science And Clinical Practice, 2nd Edition

A2 - Mydlo, JH

A2 - Godec, CJ

PB - Elsevier Inc.

ER -

Neuroendocrine Prostate Cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this